

petition fees required to consider this paper or keep the application pending may also be charged to Deposit Account 02-1375.

AMENDMENT

In the Claims:

Amend claims 26, 29, 30, 40, 43, 47, and 48, and

Insert new claims 57-64, as indicated below.

C1
26. (Amended) A composition comprising an immunosuppressive agent and a recombinant adenovirus whose genome comprises a first recombinant DNA containing a [therapeutic] first gene and a second recombinant DNA containing an immunoprotective gene.

C2
29. (Amended) The composition according to claim 26, wherein the [therapeutic] first gene encodes a therapeutic protein.

30. (Amended) The composition according to claim 26, wherein the [therapeutic] first gene encodes a therapeutic RNA.

C3
40. (Amended) The composition according to claim 39, wherein one of the recombinant DNAs is inserted within the E1 region and the other within the E3 or E4 region.

C4
43. (Amended) A method for expression of a [therapeutic] gene from an adenovirus comprising consecutively or simultaneously administering an immunosuppressive agent and a recombinant adenovirus whose genome comprises a first recombinant DNA containing the [therapeutic] gene and a second recombinant DNA containing an immunoprotective gene, to a subject.

C5
47. (Amended) The method according to claim 43, wherein the [therapeutic] gene encodes a therapeutic protein.

RECEIVED

AUG 29 2003

TECH CENTER 16007200

C5 cont.
48. (Amended) The method according to claim 43, wherein the [therapeutic] gene encodes a therapeutic RNA.

New claims 57-64:

C6
--57. The composition according to claim 26, wherein the first gene is selected from the group consisting of p53, aFGF, bFGF, factor VIII, and factor IX genes.

58. The composition according to claim 57, wherein the first gene is p53.

59. The method according to claim 43, wherein the gene is selected from the group consisting of p53, aFGF, bFGF, factor VIII, and factor IX genes.

60. The method according to claim 59, wherein the gene is p53.

61. A method of prolonging the survival of a cell expressing a gene of interest, comprising

introducing a recombinant adenovirus to a cell of an animal, the genome of the adenovirus comprising a first recombinant DNA containing the gene of interest and a second recombinant DNA containing an immunoprotective gene,

treating the animal with an immunosuppressive agent, and

detecting the presence of mRNA or protein expressed from the gene of interest.

62. The method according to claim 61, wherein the gene of interest is a therapeutic gene.

63. The method according to claim 62, wherein the gene of interest is selected from the group consisting of p53, aFGF, bFGF, factor VIII, and factor IX genes.

64. The method according to claim 63, wherein the gene of interest is p53.--